Background-The high mortality rate in end-stage renal disease has engendered interest in nontraditional atherosclerotic cardiovascular disease (ASCVD) risk factors that are more prevalent in end-stage renal disease, such as elevated lipoprotein(a) [Lp(a)] levels. Previous studies suggest that high Lp(a) levels and small apolipoprotein(a) [apo(a)] isoform size are associated with ASCVD, but none have investigated the relationship between Lp(a) level, apo(a) size, and mortality. Methods and Results-An inception cohort of 864 incident dialysis patients was followed prospectively. Lp(a) was measured by an apo(a) size-independent ELISA and apo(a) size by Western blot after SDS-agarose gel electrophoresis. Comorbid conditions were determined by medical record review. Time to death was ascertained through dialysis clinic and Health Care Financing Administration follow-up. Survival analyses were performed with adjustment for baseline demographic, comorbid conditions, albumin, and lipids. Median follow-up was 33.7 months, with 346 deaths, 162 transplantations, and 10 losses to follow-up during 1999 person-years of follow-up. Cox regression analysis showed no association between Lp(a) level and mortality. However, an association between small apo(a) isoform size and mortality was found (hazard ratio, 1.36; Pϭ0.004) after adjusting for age, race, sex, comorbidity score, cause of renal disease, and congestive heart failure. The association was somewhat lower in white patients (hazard ratio 1.34; Pϭ0.019) than in black patients (1.69; Pϭ0.04). No interaction by age, race, sex, diabetes, ASCVD, or Lp(a) level was present. Conclusions-Small apo(a) size, but not Lp(a) level, independently predicts total mortality risk in dialysis patients.
T he contribution of atherosclerotic cardiovascular disease (ASCVD) to the extraordinarily high mortality in endstage renal disease (ESRD) 1, 2 has generated interest in nontraditional ASCVD risk factors that are prevalent in ESRD, such as lipoprotein(a) [Lp(a)]. Lp(a), an atherogenic lipoprotein, consists of an LDL-cholesterol particle covalently bonded to apolipoprotein(a) [apo(a)], a glycoprotein with a genetic-size polymorphism. 3 Lp(a) level is strongly and negatively associated with apo(a) isoform size 4 and is elevated in dialysis patients, 5 suggesting that Lp(a) level or small apo(a) size may account for a portion of the increased ASCVD or mortality in the ESRD population.
Prospective studies of Lp(a) and ASCVD in ESRD have yielded conflicting results. 6 -8 The largest study in this population to date found that incident ASCVD was associated with small apo(a) size but not with a high Lp(a) level, 6 and at least one prospective study found Lp(a) level not to be associated with total mortality among dialysis patients. 9 Because no previous studies, to our knowledge, have evaluated an association between apo(a) size and total mortality in any population, we tested the a priori hypothesis that elevated Lp(a) level and small apo(a) size predict mortality in a nationally representative cohort of patients beginning dialysis.
Methods

Study Design and Population
The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study is a prospective study of outcomes among incident dialysis patients. From October 1995 to June 1998, 1041 participants from 19 states were enrolled from 81 dialysis clinics associated with Dialysis Clinic, Incorporated (DCI, Nashville, Tenn; nϭ923 from 79 clinics), New Haven CAPD (New Haven, Conn; nϭ86 from 1 clinic), or Saint Raphael's Hospital (New Haven, Conn; nϭ32 from 1 clinic). Blood was drawn only from participants enrolled at the DCI clinics, of whom 864 (93.6%) had Lp(a) measured. Participants were recruited a median of 1.6 months after first dialysis (98% within 4 months). Enrollment criteria included initiation of dialysis in the preceding 3 months, ability to give written informed consent, age over 17 years, and ability to speak English or Spanish. Trained recruiters at each clinic presented the study to all new dialysis patients during the recruitment period. The Johns Hopkins University School of Medicine Institutional Review Board and the review boards for the clinical centers approved the protocol.
Data Collection
Serum was collected before a dialysis session, centrifuged, sent overnight to the DCI Central Laboratory, stored at Ϫ80°C, and sent on dry ice to the Northwest Lipid Research Laboratory, University of Washington, Seattle, for Lp(a) assay. Sample draw occurred at a median of 4.4 months after first dialysis (95% within 6.8 months).
Lp(a) concentration was measured by a direct-binding double monoclonal antibody-based enzyme-linked immunoassay (ELISA), as previously reported. 4 The detection antibody is directed to a nonrepeating epitope present in apo(a) K-IV type 9, making this assay insensitive to apo(a) size. Lp(a) concentrations were expressed in nanomoles per liter (nmol/L). The coefficient of variation (CV) of log-Lp(a) based on 49 blindly split samples from the CHOICE cohort was 6.8%.
Apo(a) isoforms were characterized using a high-resolution SDSagarose gel electrophoresis method followed by immunoblotting, as previously reported. 10 We used a size designation related to each isoform's number of K-IV repeats. 10, 11 The CV for apo(a) size in the CHOICE cohort was 11.7% (nϭ49). An exact match of the smallest allele size for the 49 blindly split samples was present for 48.9%, and a match Ϯ1 repeat was present for 93.8%.
On a participant's death, records and study forms are sent from the dialysis clinic to the data coordinating center, and vital status are verified actively every 3 months. For 107 of 117 individuals who left the study for reasons other than renal transplantation, vital status was passively determined using Health Care Financing Administration data.
Age, race, sex, and tobacco use were obtained from patient questionnaires. The average of all predialysis session systolic and diastolic blood pressures for the baseline 3-month period was determined for each participant (average, 31 blood pressure readings per participant). The prevalence of hypertension (blood pressure Ͼ140/90), diabetes, congestive heart failure (CHF), and cardiovascular disease (defined as any history of myocardial infarction, cardiac revascularization procedure, stroke, carotid endarterectomy, peripheral vascular disease or revascularization procedure, angina, or stress test positive for ischemia) was determined from review of dialysis clinic records by one of two dialysis research nurses. Mention of a condition (past or present) in the medical record was sufficient for positive coding. A validated composite baseline comorbidity score (range, 0 to 3) derived from the Index of Co-Existent Disease (ICED) was calculated (Kappaϭ0.93, based on 45 charts blindly reviewed by both nurses). 12 
Statistical Analysis
Statistical analyses were performed with Stata (version 6.0). The Mann-Whitney U test was used to test for differences in median values of skewed variables. All analyses of apo(a) size used the predominantly expressed isoform. Lp(a) was dichotomized at the median and log-transformed when analyzed continuously. Apo(a) size was dichotomized at 22 K-IV repeats. Both were also analyzed by quartile and tested for trend across quartiles.
Survival time was defined as time from exposure ascertainment (ie, blood draw) to death or censoring. The time scale used in the analysis was time from first dialysis, with staggered entry at time of exposure ascertainment. To allow for stable early survival estimates, entry was left-truncated at 4.0 months after first dialysis.
Of the 872 participants with Lp(a) measured, 8 were not eligible for inclusion in survival analyses because they had Lp(a) measured after withdrawal from the study or were closed out before the 4.0-month entry. Of the 864 analyzed, 346 (40.1%) died, 10 (1.1%) were lost to follow-up, 162 (18.8%) were censored on renal transplantation to avoid an informative censoring bias, and the remainder were censored administratively on November 1, 2000.
Several groups of covariates were selected a priori for inclusion in Cox regression models. Group 1 included baseline dialysis modality, age, race, and sex. Group 2 added the ICED score, cause of renal disease, and CHF (CHF was chosen over ASCVD because it predicted mortality more strongly than ASCVD). Group 3 added albumin, total cholesterol, HDL-cholesterol, smoking status, and systolic blood pressure. Substitution of diastolic blood pressure, mean arterial pressure, or pulse pressure for systolic blood pressure made negligible differences in the model estimates. A priori stratified analyses investigating interactions were also performed by race, sex, age, diabetes, ASCVD, Lp(a) level, and apo(a) size. No variables were found to violate the proportionality assumption of the Cox model.
Results
Cohort characteristics are described in Table 1 Figure 1 shows no trend in death rate by Lp(a) level but a significant negative trend across apo(a) size among black patients and a trend approaching significance across apo(a) size among white patients. No black patients had an apo(a) size Ͻ13 K-IV repeats, and only one black patient had an apo(a) size Ͼ36 K-IV repeats. Figure 2 demonstrates lower survival among white than black patients but no association with Lp(a) level within race strata. However, participants with low-molecular-weight (LMW) (Յ22 K-IV repeats) apo(a) size had statistically significant lower survival among black patients and a trend toward lower survival among white patients.
The association between LMW apo(a) size and mortality remained after adjustment for all 3 groups of covariates ( Table 2) . The association was similar in white and black patients, although the estimate for black patients was not statistically significant (P interaction by raceϭ0.38). The test for trend across apo(a) size quartile was significant in all models. No interaction by age, race, sex, diabetes, prevalent cardiovascular disease (CVD), or Lp(a) level was present (Table 3 ). Lp(a) level was not associated with mortality in any Cox regression models.
Discussion
An association between small apo(a) size and incident AS-CVD has been previously described in ESRD, 6 but to our knowledge, no studies have reported the relationship between apo(a) size and total mortality in any population. This study identifies small apo(a) size as a new and independent risk factor of moderate magnitude for total mortality in a cohort of incident dialysis patients but finds no association between Lp(a) level and mortality. This focus on total mortality is important particularly among dialysis patients, because the mortality in this population is so high. Furthermore, some ASCVD risk factors may not predict total mortality. Those that do, such as small apo(a) size in this study, may have greater public health impact than those that do not predict total mortality.
Previous Studies of Lp(a) and apo(a) in the General Population
The association between Lp(a) level and coronary heart disease (CHD) has been studied extensively in the general population. A meta-analysis of 18 prospective studies found an overall risk ratio of 1.7 (95% CI, 1.4 to 1.9) for fatal and nonfatal CHD comparing the upper and lower Lp(a) tertiles. 13 The HERS trial reported similar relative risks of CHD in postmenopausal women, finding that estrogen replacement therapy significantly lowers Lp(a) level and confers a greater CHD protective benefit in those with high Lp(a) levels compared with those with low Lp(a). 14 Fewer prospective studies of apo(a) isoform size and CHD in the general population have been published. [15] [16] [17] The largest nested case-control study of Lp(a), apo(a), and incident CHD in the general population (nϭ134 cases) found an association between Lp(a) and CHD but not between apo(a) size and CHD, although the crude analysis showed a trend toward smaller apo(a) size among cases. 15 The prospective studies of apo(a) size were not large enough to study mortality, and the largest studies of Lp(a) level, which might have had the power to analyze mortality, did not measure apo(a) size.
Potential Atherogenic Mechanisms of Lp(a) and apo(a)
The 80% sequence homology of the apo(a) K-IV moiety with plasminogen and in vitro findings that Lp(a) inhibits fibrino- 18 suggests that Lp(a) may contribute to acute thrombotic events. Hervio et al 19 reported that the LMW apo(a) isoforms bind more strongly to fibrin than larger isoforms. This provides a possible mechanism by which apo(a) isoform size itself, not only the associated Lp(a) level, becomes important in accelerating atherosclerosis, particularly after significant atherosclerosis has already been established. Nevertheless, in this mechanism, Lp(a) level would probably still be expected to play a significant role, because more apo(a) would be available to inhibit fibrinolysis, and an interaction between Lp(a) level and apo(a) size in the association with incident ASCVD or mortality could result. Kronenberg and colleagues found an association between Lp(a) and progression of atherogenesis and incident CVD restricted to those with no baseline atherosclerosis. In contrast, they found an association between small apo(a) isoform size and progression to advanced atherosclerosis restricted to those with baseline atherosclerosis. 17 The results of that study suggest that Lp(a) may act primarily as an atherogenic lipid (via its LDL-like portion) in vessels with little or no atherosclerosis, whereas in the setting of advanced atherosclerosis, the antifibrinolytic action of the apo(a) protein may play a more significant role.
Our finding of an association between small apo(a) size and mortality supports this proposed mechanism, because atherosclerosis is so highly prevalent in ESRD. Furthermore, although there was insufficient evidence of interaction by prevalent CVD (Table 3) , we did find a higher risk of death for LMW isoforms among those with prevalent CVD than without.
Lp(a) Level, apo(a) Size, and Mortality in ESRD
The only prospective study of Lp(a) level, apo(a) size, and CHD in ESRD, which followed 440 dialysis patients for 5 years and accrued 66 CHD events, found that LMW apo(a) size, not Lp(a) level, was associated with the development of CHD (adjusted hazard ratio [HR]ϭ2.3; Pϭ0.0008). 6 Kronenberg and colleagues have developed an interesting hypothesis based on their finding that among those with HMW apo(a) isoforms, Lp(a) levels are much higher in ESRD than in apo(a) phenotype-matched population controls, whereas among those with LMW isoforms, the Lp(a) level in ESRD patients is not significantly higher than that of phenotypematched population controls, who already have high Lp(a) levels. 5 This implied differential change in Lp(a) by apo(a) subtype over the course of progression to renal disease would diminish the association between Lp(a) and ASCVD in ESRD. Furthermore, the hypothesis states that in dialysis patients, apo(a) isoform size would more accurately reflect Lp(a) levels actually experienced over the long term, identify those with a more damaged vascular endothelium at the beginning of ESRD, and therefore possibly identify those who would develop ASCVD at a much higher rate. 20 On the other hand, apo(a) size remains the strongest predictor of Lp(a) levels even after ESRD develops. In our cohort, apo(a) size alone accounts for Ϸ38% of the variability The present study found no association between Lp(a) level and mortality. These findings are consistent with the study by Koch et al, 9 who measured Lp(a) level but not apo(a) size in 130 dialysis patients followed for 36 months, finding no association between Lp(a) level and survival. Several potential explanations exist for the null finding for Lp(a) level in light of the positive association with apo(a) size. First, our results are consistent with Kronenberg's hypothesis, which would predict a stronger association between apo(a) size and have serum banked and have long follow-up periods and sufficient deaths already accrued for analysis.
